Damaged capsules have been identified in batches of Lenalidomide Mylan, with powder visible inside the blister pocket. For all strengths and pack sizes, healthcare professionals should carefully inspect blisters and avoid dispensing packs with any damaged capsule. Such packs must be returned for replacement; undamaged packs may be dispensed with strict handling precautions. Women who […]
The Medicines and Healthcare products Regulatory Agency (MHRA) uncovered and shut down the UK’s first illegal weight loss medicine factory during a raid on a Northampton warehouse. This facility, believed to be the largest of its kind seized globally, was producing and distributing unlicensed and potentially dangerous weight loss injections. Officers from the MHRA’s Criminal […]
The FDA is now raising awareness regarding administration of tranexamic acid injections to be limited only to intravenous administration. There have been case reports where tranexamic acid was mistakenly injected neuraxially instead of intravenously, resulting in serious patient outcomes, including prolonged hospitalization and death. Tranexamic acid injection is approved for short-term use (2–8 days) in […]
The European Medicines Agency (EMA) in coordination with The Federal Institute for Drugs and Medical Devices (BfArM) has raised concerns regarding Caspofungin containing products, after finding that patients treated with Caspofungin who undergo continuous renal replacement therapy (CRRT) made of polyacrylonitrile (PAN)-based membranes should be avoided as it decreases effectiveness of medication. This has resulted […]
The U.S. Food and Drug Administration (FDA) is taking proactive steps to protect public health following alarming reports of diethylene glycol (DEG) and ethylene glycol (EG) contamination in children’s cough and cold medicines produced in India. The agency confirmed that none of the affected products have entered the U.S. market, and India’s Central Drugs Standard […]
The European Medicines Agency (EMA) has announced new safety measures for finasteride- and dutasteride-containing medicines to decrease the risk of suicidal ideation. These updates aim to increase awareness among healthcare professionals and patients regarding possible mood-related side effects associated with these treatments. Lower-dose oral finasteride (1 mg) is used to treat early-stage male pattern hair […]
April to June 2025 saw the FDA’s Adverse Event Reporting System (FAERS) report a series of possible safety signals and new serious risk warnings for a range of medicines. Although these signals do not yet establish causality, they warn regulators, physicians, and patients of possible risks to be evaluated further and warned about. The collection […]
Submit RFI/RFP
Request Consultation